ArticleHealthcare (Basel, Switzerland)2020
A Robust Discriminant Framework Based on Functional Biomarkers of EEG and Its Potential for Diagnosis of Alzheimer's Disease.
Article in Healthcare (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The EEG analysis and identification of Alzheimer's disease: a review.Frontiers in aging neuroscience · 2025Pooled it
- Translational approach for dementia subtype classification using convolutional neural network based on EEG connectome dynamics.Scientific reports · 2025Article
- A Novel Working Memory Task-Induced EEG Response (WM-TIER) Feature Extraction Framework for Detecting Alzheimer's Disease and Mild Cognitive Impairment.Biosensors · 2025Article
- Physiological Noise Filtering in Functional Near-Infrared Spectroscopy Signals Using Wavelet Transform and Long-Short Term Memory Networks.Bioengineering (Basel, Switzerland) · 2023Article
- A novel method for diagnosing Alzheimer's disease using deep pyramid CNN based on EEG signals.Heliyon · 2023Article
- Motor imagery EEG signal classification with a multivariate time series approach.Biomedical engineering online · 2023Article
- Discriminant Subspace Low-Rank Representation Algorithm for Electroencephalography-Based Alzheimer's Disease Recognition.Frontiers in aging neuroscience · 2022Article
- Electroencephalography as a Non-Invasive Biomarker of Alzheimer's Disease: A Forgotten Candidate to Substitute CSF Molecules?International journal of molecular sciences · 2021Review
- Comparison of Smoothing Filters' Influence on Quality of Data Recorded with the Emotiv EPOC Flex Brain-Computer Interface Headset during Audio Stimulation.Brain sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
(1) Background: Growing evidence suggests that electroencephalography (EEG), recording the brain's electrical activity, can be a promising diagnostic tool for Alzheimer's disease (AD). The diagnostic biomarkers based on quantitative EEG (qEEG) have been extensively explored, but few of them helped clinicians in their everyday practice, and reliable qEEG markers are still lacking. The study aims to find robust EEG biomarkers and propose a systematic discrimination framework based on signal processing and computer-aided techniques to distinguish AD patients from normal elderly controls (NC). (2) Methods: In the proposed study, EEG signals were preprocessed firstly and Maximal overlap discrete wavelet transform (MODWT) was applied to the preprocessed signals. Variance, Pearson correlation coefficient, interquartile range, Hoeffding's D measure, and Permutation entropy were extracted as the input of the candidate classifiers. The AD vs. NC discriminant performance of each model was evaluated and an automatic diagnostic framework was eventually developed. (3) Results: A classification procedure based on the extracted EEG features and linear discriminant analysis based classifier achieved the accuracy of 93.18 ± 3.65 (%), the AUC of 97.92 ± 1.66 (%), the F-measure of 94.06 ± 4.04 (%), separately. (4) Conclusions: The developed discrimination framework can identify AD from NC with high performance in a systematic routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.